Hickman Dean, Vasavanonda Sudthida, Nequist George, Colletti Lynn, Kati Warren M, Bertz Richard, Hsu Ann, Kempf Dale J
Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois 60064, USA.
Antimicrob Agents Chemother. 2004 Aug;48(8):2911-7. doi: 10.1128/AAC.48.8.2911-2917.2004.
Using measured free fraction and 50% inhibitory concentration (IC50) values for the human immunodeficiency virus protease inhibitors lopinavir (LPV) and ritonavir (RTV) in tissue culture media with various protein concentrations ranging from 5 to 50%, we estimated serum-free IC50 values for each drug. The range of serum-free IC50 values (0.64 to 0.77 ng/ml for LPV and 3.0 to 5.0 ng/ml for RTV) did not exhibit a trend with increasing protein concentrations, despite a 10-fold difference in the free fraction value (0.006 to 0.063) for LPV and a 5-fold difference in the free fraction value (0.013 to 0.057) for RTV. The mean serum-free IC50 by the MTT-MT4 assay (0.69 ng/ml for LPV and 4.0 ng/ml for RTV) may be the most accurate parameter for the estimation of the inhibitory quotient (IQ), a relative measure of in vivo potency defined as the ratio of the minimal free drug concentration in plasma (C(trough,free)) for a specific patient population and the serum-free IC50. Using this approach, we calculated the average IQs for protease inhibitor-naïve patients for LPV and RTV to be 67 and 5.6, respectively.
在蛋白质浓度为5%至50%的各种组织培养基中,利用测得的人免疫缺陷病毒蛋白酶抑制剂洛匹那韦(LPV)和利托那韦(RTV)的游离分数和50%抑制浓度(IC50)值,我们估算了每种药物的无血清IC50值。尽管LPV的游离分数值有10倍差异(0.006至0.063),RTV的游离分数值有5倍差异(0.013至0.057),但无血清IC50值范围(LPV为0.64至0.77 ng/ml,RTV为3.0至5.0 ng/ml)并未随蛋白质浓度增加呈现出一种趋势。通过MTT-MT4测定法得到的平均无血清IC50(LPV为0.69 ng/ml,RTV为4.0 ng/ml)可能是估算抑制商(IQ)的最准确参数,抑制商是体内效价的一种相对度量,定义为特定患者群体血浆中最小游离药物浓度(C(谷值,游离))与无血清IC50的比值。采用这种方法,我们计算出初治蛋白酶抑制剂患者中LPV和RTV的平均IQ分别为67和5.6。